Combined BRAF and MEK Inhibition With Dabrafenib and Trametinib in BRAF V600–Mutant Colorectal Cancer | Zendy

Ryan B. Corcoran | Zendy; Chloé E. Atreya | Zendy; Gerald S. Falchook | Zendy; Eunice L. Kwak | Zendy; David P. Ryan | Zendy; Johanna C. Bendell | Zendy; Omid Hamid | Zendy; Wells A. Messersmith | Zendy; Adil Daud | Zendy; Razelle Kurzrock | Zendy; Mariaelena Pierobon | Zendy; Peng Sun | Zendy; Elizabeth Cunningham | Zendy; Shonda M Little | Zendy; Keith Orford | Zendy; Monica Motwani | Zendy; Yuchen Bai | Zendy; Kiran Klaus Patel | Zendy; Alan P. Venook | Zendy; Scott Kopetz | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Combined BRAF and MEK Inhibition With Dabrafenib and Trametinib in BRAF V600–Mutant Colorectal Cancer

Author(s) -

Ryan B. Corcoran,

Chloé E. Atreya,

Gerald S. Falchook,

Eunice L. Kwak,

David P. Ryan,

Johanna C. Bendell,

Omid Hamid,

Wells A. Messersmith,

Adil Daud,

Razelle Kurzrock,

Mariaelena Pierobon,

Peng Sun,

Elizabeth Cunningham,

Shonda M Little,

Keith Orford,

Monica Motwani,

Yuchen Bai,

Kiran Klaus Patel,

Alan P. Venook,

Scott Kopetz

Publication year - 2015

Publication title -

journal of clinical oncology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 10.482

H-Index - 548

eISSN - 1527-7755

pISSN - 0732-183X

DOI - 10.1200/jco.2015.63.2471

Subject(s) - trametinib , dabrafenib , medicine , mek inhibitor , colorectal cancer , pten , cancer research , melanoma , oncology , biopsy , cancer , kinase , mapk/erk pathway , pi3k/akt/mtor pathway , vemurafenib , biology , signal transduction , metastatic melanoma , biochemistry , microbiology and biotechnology

To evaluate dabrafenib, a selective BRAF inhibitor, combined with trametinib, a selective MEK inhibitor, in patients with BRAF V600-mutant metastatic colorectal cancer (mCRC).

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research